Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib with Oxaliplatin and Capecitabine for Advanced Gastric Cancer
NCT00256321Phase 2Terminated
- Sponsor
- University of California, Irvine
- Start
- Oct 2004
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by University of California, Irvine. Primary endpoints: Response rate of patients with gastric/gastroesophageal carcinoma at 18 weeks and Time to progression at 18 weeks. Started Oct 2004; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00256321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256321.